A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects
Andi Leubitz, Frederic Vanhoutte, Ming-Yi Hu, Kaela Porter, Efrat Gordon, Kathleen Tencer, Kathleen Campbell, Kate Banks, Tom Haverty, Andi Leubitz, Frederic Vanhoutte, Ming-Yi Hu, Kaela Porter, Efrat Gordon, Kathleen Tencer, Kathleen Campbell, Kate Banks, Tom Haverty
Abstract
ELX-02 is an investigational compound being developed as a therapy for genetic diseases caused by nonsense mutations such as cystic fibrosis. Structurally, ELX-02 is an aminoglycoside analogue that induces read-through of nonsense mutations through interaction with the ribosome, resulting in the production of full-length functional proteins. This phase 1 multiple-ascending-dose trial evaluated the safety and pharmacokinetics of ELX-02 in 62 healthy volunteers. ELX-02 plasma exposure was dose proportional, with no apparent accumulation, and followed by renal elimination. The most reported adverse event was injection site reactions that were mild to moderate in severity. At the top dose of 5.0 mg/kg, 1 of 6 subjects experienced auditory threshold changes in which ototoxicity could not be clearly ruled out, and 2 of 6 had hearing threshold changes consistent with possible ototoxicity. Two of 3 subjects receiving placebo in the 5.0 mg/kg group also had significant hearing threshold changes. All observed hearing threshold changes resolved or were trending toward resolution after withdrawal of the study drug. No severe or serious adverse events were reported.The results of this study support the evaluation of ELX-02 in phase 2 clinical trials with patients that have genetic diseases caused by nonsense mutations.
Keywords: ELX-02; cystic fibrosis; nonsense mutations; pharmacokinetics; phase 1; safety.
Conflict of interest statement
A.L., M.‐Y.H., E.G., K.T., K.B., and T.H. are employees of Eloxx Pharmaceuticals, Inc. F.V. was a principal investigator for the study. K.P. and K.C. are consultants to Eloxx Pharmaceuticals, Inc.
© 2021 Eloxx Pharmaceuticals. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
Figures
References
- Mort M, Ivanov D, Cooper DN, et al. A meta‐analysis of nonsense mutations causing human genetic disease. Hum Mutat. 2008;29(8):1037‐1047.
- Linde L, Kerem B.Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet. 2008;24:552‐563.
- McCague AF, Raraigh KS, Pellicore MJ, et al. Correlating cystic fibrosis transmembrane conductance regulator function with clinical features to inform precision treatment of cystic fibrosis. Am J Respir Crit Care Med. 2019;199(9):1116‐1126.
- Gahl WA, Thoene JG, Schneider JA.Cystinosis N Engl J Med. 2002;347:111‐121.
- Brasell EJ, Chu LL, Akpa MM, et al. The novel aminoglycoside, ELX‐02, permits CTNSW138X translational read‐through and restores lysosomal cystine efflux in cystinosis. PLoS One. 2019;14(12):e0223954.
- Leubitz A, Frydman‐Marom A, Sharpe N, van Duzer J, Campbell KCM, Vanhoutte F.Safety, tolerability, and pharmacokinetics of single ascending doses of ELX‐02, a potential treatment for genetic disorders caused by nonsense mutations, in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8:984‐994.
Source: PubMed